CAR-T cell therapy for severe myasthenia gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial is testing a new type of cell therapy called CAR-T that targets two proteins (CD19 and BCMA) on certain immune cells. It aims to help people with severe myasthenia gravis that has not improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with generalized myasthenia gravis and have a positive antibody test (AChR, MuSK, or LRP4).
- Your myasthenia gravis is considered 'refractory' – meaning it hasn't responded well to at least two different immune-suppressing treatments.
- You have moderate to severe muscle weakness (MGFA class II to IVa) and a symptom score of at least 11 on the QMGS scale or 5 on the MG-ADL scale.
- You have not taken certain medications (like rituximab in the last 6 months, or tocilizumab, eculizumab, IVIg, or plasma exchange in the last month).
- You do not have active infections, certain blood test abnormalities, or other serious health conditions like HIV or hepatitis B.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
This trial tests an experimental cell therapy (UCAR T-cells) that targets two markers on immune cells to treat myasthenia gravis that hasn't improved with standard treatments. It aims to reduce symptoms and improve daily functioning.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
This trial tests a new cell therapy called anitocabtagene autoleucel (anito-cel) for people with generalized myasthenia gravis (gMG) that is not well controlled with current treatments. The goal is to see if it can reduce symptoms and improve quality of life.
This trial tests a new kind of cell therapy (UCAR-T) that targets CD19 and BCMA proteins on immune cells. It is for people with certain neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis who have not responded well to standard treatments.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.